Nanoparticle Delivery of Autoantigens to Liver Cells for Treg Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating regulatory T cells for autoimmune disease treatment are not effectively translated into clinically applicable therapies, and gene transfer methods pose associated problems.
Innovation Solution
A pharmaceutical composition comprising nanoparticles with a micelle structure and a peptide comprising a T cell epitope, designed to target liver sinusoidal endothelial cells for the in vivo generation of regulatory T cells, which are capable of suppressing autoimmune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If gene transfer methods are used to generate regulatory T cells, then Treg generation is achieved, but safety issues and clinical applicability problems arise
Solution Approach 1:
The patent uses hepatocytes as intermediary cells to deliver autoantigens to the immune system. Instead of directly transferring genes to generate Tregs, the autoantigens are expressed in hepatocytes which then present them to T cells, indirectly inducing Treg generation. This intermediary approach avoids the safety issues of direct gene transfer while maintaining the ability to generate therapeutic Tregs.
Solution Approach 2:
The patent replaces the mechanical/biological process of gene transfer with a protein expression approach. Rather than introducing genetic material that requires cellular machinery to function, the autoantigens are expressed as proteins in hepatocytes, which are then naturally processed and presented by MHC molecules. This substitution eliminates the safety concerns associated with gene transfer while achieving the same immunological effect.
2Reliability
If adoptive transfer of Treg cells is performed, then autoimmune disease prevention is achieved, but the complexity of therapy increases
Solution Approach 1:
The patent enables the patient's own body to generate the required Treg cells through the administration of autoantigens. The hepatocytes express the autoantigens, which are then naturally processed and presented to naive T cells, inducing their conversion to Tregs in situ. This self-service approach eliminates the need for ex vivo Treg isolation, expansion, and reinfusion procedures, significantly simplifying the therapy while maintaining disease prevention efficacy.
3Productivity
If conventional T cell stimulation methods are used, then T cell activation occurs, but regulatory T cell generation is insufficient
Solution Approach 1:
The patent creates a specific local environment in the liver where autoantigens are expressed in hepatocytes. This local presentation of autoantigens in the tolerogenic liver environment selectively promotes Treg generation from stimulated T cells, while conventional stimulation methods elsewhere would lead to effector T cell activation. The local quality of the liver microenvironment thus directs the differentiation outcome toward Tregs.
Solution Approach 2:
The patent changes the parameter of antigen presentation location from conventional lymphoid organs to the liver. By expressing autoantigens in hepatocytes rather than using conventional dendritic cell-based stimulation, the patent exploits the unique tolerogenic properties of the liver environment to shift the stimulation outcome from effector T cell activation to Treg generation, thereby improving Treg productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles effectively induce regulatory T cells specific to the associated peptide, demonstrating the ability to suppress experimental autoimmune encephalitis in animal models, providing a promising approach for treating autoimmune diseases.
Implementation Method 1
nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells
Implementation Method 2
peptide to T cells via MHC molecules
Implementation Method 3
Treg feature several secreted or membrane-bound molecules that communicate inhibitory signals to other effector T cells, thereby suppressing proliferation and inflammatory cytokine secretion
Data Source
AI summary
The present invention relates to nanoparticles for the targeted delivery of antigen to liver cells, in particular, liver sinusoidal endothelial cells (LSEC) and/or Kupffer cells, and for the in vivo generation of regulatory T cells, notably CD4+CD25+FOXP3+ regulatory T cells (Treg). The invention provides pharmaceutical compositions and methods for the prevention and treatment of autoimmune diseases, allergies or other chronic inflammatory conditions, and for generation of regulatory T cells. The nanoparticles used in the invention comprise a) a micelle comprising an amphiphilic polymer rendering the nanoparticle water-soluble, and b) a peptide comprising at least one T cell epitope associated with the outside of the micelle. The micelle may or may not comprise a solid hydrophobic core.